Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Czechia
Czechia- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
45 trials match your criteria
Recruiting
Arteriosclerosis
RecruitingInvestigational
Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease
Investigational
- Disease:Arteriosclerosis
- Substances:Maridebart Cafraglutide
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Maridebart Cafraglutide
Recruiting
Acute myocardial infarction
RecruitingInvestigational
Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History
Investigational
- Disease:Acute myocardial infarction
- Substances:Selatogrel
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Selatogrel
Recruiting
Secondary progressive multiple sclerosis
RecruitingInvestigational
A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
- Disease:Secondary progressive multiple sclerosis
- Substances:Remibrutinib
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Remibrutinib
Recruiting
Relapsing multiple sclerosis
RecruitingRegistered drugNo placebo
Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment
Registered drugNo placebo
- Disease:Relapsing multiple sclerosis
- Substances:OcrelizumabRemibrutinib
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Ocrelizumab
Recruiting
Arteriosclerosis
RecruitingInvestigationalNo placebo
Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial
InvestigationalNo placebo
- Disease:Arteriosclerosis
- Substances:Pelacarsen
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Pelacarsen
Recruiting
Relapsing multiple sclerosis+2
RecruitingRegistered drug
Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis
Registered drug
- Disease:Relapsing multiple sclerosisSecondary progressive multiple sclerosis+1
- Substances:TeriflunomideTolebrutinib+2
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Teriflunomide
Not yet recruiting
Atrial fibrillation
Not yet recruitingRegistered drug
Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban
Registered drug
- Disease:Atrial fibrillation
- Substances:ApixabanRegn7508
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Apixaban
Not yet recruiting
Parkinson's disease
Not yet recruitingRegistered drug
A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease
Registered drug
- Disease:Parkinson's disease
- Substances:Ioflupane (123I)
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Ioflupane (123I)
Not yet recruiting
Relapsing-remitting multiple sclerosis
Not yet recruitingRegistered drugNo placebo
Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis
Registered drugNo placebo
- Disease:Relapsing-remitting multiple sclerosis
- Substances:Ocrelizumab
Countries:Czechia
Czechia- Participants:18–64 years
- Substances:Ocrelizumab
Not yet recruiting
Nervous system disorder
Not yet recruitingRegistered drugNo placebo
Continued Access Study for Patients with Neurological Disease Using Ocrelizumab and Drug Combination
Registered drugNo placebo
- Disease:Nervous system disorder
- Substances:OcrelizumabDexamethasone Acetate+2
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Ocrelizumab
Not recruiting
Obesity
Not recruitingInvestigational
Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes
Investigational
- Disease:Obesity
- Substances:–
Countries:Czechia
Czechia- Participants:18–64 years · 65+ years